Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure
نویسندگان
چکیده
منابع مشابه
CYP2C19 Phenoconversion by Routinely Prescribed Proton Pump Inhibitors Omeprazole and Esomeprazole: Clinical Implications for Personalized Medicine.
The phenotype pantoprazole-(13)C breath test (Ptz-BT) was used to evaluate the extent of phenoconversion of CYP2C19 enzyme activity caused by commonly prescribed proton pump inhibitors (PPI) omeprazole and esomprazole. The Ptz-BT was administered to 26 healthy volunteers and 8 stable cardiovascular patients twice at baseline and after 28 days of PPI therapy to evaluate reproducibility of the Pt...
متن کاملAnthocyanins and anthocyanidins are poor inhibitors of CYP2D6.
The cytochrome P450 CYP2D6 isoform is involved in the metabolism of about 50% of all psychoactive drugs, including neuroleptic agents, selective serotonin reuptake inhibitors, selective norepinephrine reuptake inhibitors and tricyclic antidepressants. Therefore, inhibition of cytochrome P450 activity by foodstuffs has implications for drug safety. The present study addresses inhibitory effects ...
متن کاملDevelopment of Parkinsonism following exposure to aripiprazole: two case reports
INTRODUCTION Aripiprazole is a novel atypical neuroleptic used in the treatment of psychosis. A few recent studies have demonstrated an association between the use of aripiprazole and an exacerbation of Parkinsonism, although this relationship is poorly defined. To our knowledge, this is the first case series describing an onset of Parkinsonism in patients without prior history of Parkinson's d...
متن کاملRapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR.
BACKGROUND Interindividual differences in CYP2D6 activity range from total absence of metabolism of certain drugs to ultrafast metabolism and can produce adverse effects or lack of therapeutic effect under standard therapy. Several mutations have been described in the CYP2D6 gene that abolish CYP2D6 activity. However, four mutations explain the majority of the poor metabolizers. We describe fou...
متن کاملPhenoconversion and Therapeutic Drug Monitoring
Disclosures of Competing Interests: This letter to the editor was completed without any external funding. 18 No commercial organizations had any role in the writing of this paper for publication. 20 request from the corresponding author) and declares: no financial relationships with any organizations that 21 might have an interest in the submitted work in the previous 3 years.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Archives of Psychiatry and Clinical Neuroscience
سال: 2019
ISSN: 0940-1334,1433-8491
DOI: 10.1007/s00406-018-0975-2